RTP Mobile Logo
Oncology Nursing Update, Lymphoma and Multiple Myeloma Edition, Issue 1, 2017 (Video Program)
Released November 2017

Proceedings from video interviews with Ms Amy Goodrich and Drs John P Leonard, Jonathan L Kaufman and Kevin Brigle on the treatment of lymphomas and multiple myeloma. (Video Program)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    The past several years represents a period of substantial progress in the development and evaluation of novel agents in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). This dynamic therapeutic environment necessitates that the practicing oncology nurse remain up to date on the benefits and risks of a plethora of novel and emerging treatment options. To provide oncology nurses with therapeutic strategies to address the disparate needs of patients, the Oncology Nursing Update audio series employs one-on-one interviews with nurses and medical oncologists who are experts in the field. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with NHL, CLL and MM.

    PURPOSE STATEMENT
    To present the most current research developments and to provide the perspectives of nurse practitioners and clinical investigators on the diagnosis and treatment of NHL, CLL and MM.

    LEARNING OBJECTIVES

    • Appreciate the contribution of patient performance status/comorbidities, biomarker profile and prior therapeutic exposure on the selection and sequence of systemic therapy for newly diagnosed and relapsed/refractory (R/R) CLL.
    • Recognize the recent FDA approval of venetoclax for the treatment of R/R CLL, and discern how this agent can be safely integrated into general oncology practice.
    • Review recent therapeutic advances in the management of follicular and mantle cell lymphoma, and use this information to counsel patients regarding protocol and clinical options.
    • Explain the risks and benefits of evidence-based treatment approaches to patients with T-cell lymphoma.
    • Evaluate the benefits and risks associated with systemic therapies used in the evidence-based treatment of MM, and develop a plan of care to manage side effects to support quality of life and continuation of treatment.
    • Effectively counsel patients regarding the expected efficacy and tolerability of newly approved therapeutics for the management of R/R MM.

    ACCREDITATION STATEMENT
    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    This educational activity for 2.9 contact hours is provided by Research To Practice during the period of November 2017 through November 2018.

    This activity is awarded 2.9 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

    To review certification qualifications please visit: ResearchToPractice.com/ONULymphMM117/Video/ILNA.

    ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    This is a video CNE program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the videos and complete the Post-test and Educational Assessment and Credit Form located at ResearchToPractice.com/ONULymphMM117/Video/CNE. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 80% or better and a completed Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

    The corresponding audio program is available as an alternative at ResearchToPractice.com/ONULymphMM117.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Amy Goodrich, CRNP-AC
    Nurse Practitioner
    Johns Hopkins Kimmel Cancer Center
    Baltimore, Maryland

    Advisory Committee: Gilead Sciences Inc.

    John P Leonard, MD
    Richard T Silver Distinguished Professor of Hematology and Medical Oncology
    Associate Dean for Clinical Research
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Genmab, Gilead Sciences Inc, Juno Therapeutics, Kite Pharma Inc, NanoString Technologies, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sunesis Pharmaceuticals Inc, Sutro Biopharma Inc.

    Jonathan L Kaufman, MD
    Associate Professor of Hematology and Medical Oncology
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Advisory Committee: Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Seattle Genetics, Sutro Biopharma Inc; Contracted Research: Merck, Novartis.

    Kevin Brigle, PhD, ANP
    VCU Massey Cancer Center
    Richmond, Virginia

    Speakers Bureau: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Celgene Corporation, Gilead Sciences Inc and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: November 2017
    Expiration date: November 2018

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Interview with Amy Goodrich, CRNP-AC

Interview with John P Leonard, MD

Interview with Jonathan L Kaufman, MD

Interview with Kevin Brigle, PhD, ANP

Select Publications